Skip to main content

Research Repository

Advanced Search

All Outputs (22)

Genetic Risk Factors in Drug?Induced Liver Injury Due to Isoniazid?Containing Antituberculosis Drug Regimens (2020)
Journal Article

Drug?induced liver injury (DILI) is a complication of treatment with anti?tuberculosis (TB) drugs, especially in isoniazid?containing regimens. To investigate genetic risk factors, we performed a genome?wide association study (GWAS) involving anti?TB... Read More about Genetic Risk Factors in Drug?Induced Liver Injury Due to Isoniazid?Containing Antituberculosis Drug Regimens.

Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation (2020)
Journal Article

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. OBJECTIVES: The increasing incidence of chronic liver disease (CLD) in the UK may be attributed to a rise in... Read More about Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation.

In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers (2020)
Journal Article

INTRODUCTION: Up to 40% of patients with severe alcoholic hepatitis (AH) die within 6 months of presentation, making prompt diagnosis and appropriate treatment essential. We determined the associations between serum keratin-18 (K18) and histologi... Read More about In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers.

Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: A large case-control study (2020)
Journal Article

The study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of COVID-19 in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zheijang, Chin... Read More about Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: A large case-control study.

Obesity, diabetes, coffee, tea and cannabis use alter risk for alcohol-related cirrhosis in two large cohorts of high-risk drinkers (2020)
Journal Article

Background: Sustained high alcohol intake is necessary but not sufficient to produce alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, would assist in discovery of mechanisms and prediction of risk.... Read More about Obesity, diabetes, coffee, tea and cannabis use alter risk for alcohol-related cirrhosis in two large cohorts of high-risk drinkers.

Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors (2020)
Journal Article

Only a minority of heavy drinkers progress to alcohol?related cirrhosis (ALC). The aim of this study was to identify common genetic variants that underlie risk for ALC. We analyzed data from 1,128 subjects of European ancestry with ALC and 614 heavy... Read More about Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.

Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers (2020)
Journal Article

Background & Aims: Carriage of rs738409:G in patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with an increased risk for developing alcohol-related cirrhosis and hepatocellular carcinoma (HCC). Recently, rs72613567:TA in hydrox... Read More about Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.

Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome (2020)
Journal Article

Background: The development of accurate, non-invasive markers to diagnose and stage non-alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an invasive liver biopsy and to identify patients who are at the highest risk of hepatic... Read More about Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort (2020)
Journal Article

Background and Aims Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most GWAS studies have adopted radiologically assessed hepatic triglyceride content as reference phenotype and s... Read More about Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study (2020)
Journal Article

Background & Aims: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. Method... Read More about Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.

L-carnitine supplementation in non-alcoholic fatty liver disease: A systematic review and meta-analysis (2020)
Journal Article

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) dominates the landscape of modern hepatology. Affecting 25% of the general population, there is critical unmet need to identify broadly available, safe and cost-effective treatments. Cumulative ev... Read More about L-carnitine supplementation in non-alcoholic fatty liver disease: A systematic review and meta-analysis.